Catalyst Event

Amgen Inc (AMGN) · Other

From KEDI Tesla Fixed Tech100 Index (KTSLT100)

6/1/2026, 12:00:00 AM

OtherSentiment: Positive

The European Commission granted marketing authorization for IMDYLLTRA® (tarlatamab) on 2026-06-01 for the treatment of ES-SCLC; expected to have a medium market impact of approximately 5% due to expanded market access.

Korean Translation

2026년 6월 1일 유럽 집행위원회(EC)가 소세포폐암(ES-SCLC) 치료제 임딜트라®(타를라타맙)의 판매 허가를 승인함. 시장 확대에 따른 약 5% 수준의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline